Clinical Trials on Male Breast Cancer in Australia

Total 2156 results

Novartis Pharmaceuticals

Completed

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)

Breast Cancer

United States, China, Belgium, Canada, France, Italy, Taiwan, United Kingdom, Hungary, Australia, Spain, Germany, Singapore, Austria, Japan, Israel, Russian Federation, Korea, Republic of, Thailand, Slovakia, South Africa, Switzer... and more
Quadriga Biosciences, Inc.
Novotech (Australia) Pty Limited

Completed

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Melanoma | Sarcoma | Kidney Cancer | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Astrocytoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Thymic Carcinoma | Lung Cancer | Prostate Cancer | Brain Cancer | Cholangiocarcinoma | Bladder Cancer | Liver Cancer | Brain Metastases | Tongue Cancer | Esophagus... and other conditions

Australia
McMaster University
Canadian Cancer Society (CCS); Prostate Cancer Canada

Recruiting

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICALPC)

Cardiovascular Disease | Prostate Cancer

United States, Canada, Australia, Brazil, Israel, Turkey, Colombia
Aptevo Therapeutics

Completed

Study of ES414 in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States, Australia
Odonate Therapeutics, Inc.

Terminated

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)

Breast Cancer

Korea, Republic of, United States, Spain, Canada, Singapore, Taiwan, Australia, Belgium, Thailand, Hungary, Germany, United Kingdom, France, Ukraine, Austria, Czechia, Italy, Poland, Russian Federation
NSABP Foundation Inc
Hoffmann-La Roche; Genentech, Inc.; Cancer International Research Group (CIRG)

Terminated

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH)

Breast Cancer

Korea, Republic of, United States, Canada, Spain, Ireland, Australia, Argentina, China, United Kingdom, Germany, Brazil, Hong Kong, France, Israel, Taiwan, Serbia, Belgium, Thailand, Croatia, Egypt, Italy, Philippines, Bosnia and Herzegovina and more
Trans Tasman Radiation Oncology Group

Unknown

Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC) (CHISEL)

Non Small Cell Lung Cancer

Australia, New Zealand
Medical University of Graz

Unknown

Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care

Quality of Life | Breast Cancer | Lung Cancer | Cholangiocarcinoma | Advanced Cancer | Pancreas Cancer | Colo-rectal Cancer | Symptoms and Signs

Austria
Dr. Elisabeth Würinger

Completed

Lymphatic Drainage of the Breast, a Retrospective Assessment of Data

Lymph Drainage of Breast

Austria
Akesobio Australia Pty Ltd

Unknown

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors

Advanced Cancer

Australia
Sunnybrook Health Sciences Centre
Exact Imaging

Recruiting

Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI (OPTIMUM)

Prostate Cancer

United States, Canada, Austria, France, Germany, Spain, Belgium
Ferronova Pty Ltd
Austin Health; Peter MacCallum Cancer Centre, Australia; Flinders Medical Centre and other collaborators

Recruiting

Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation (MAGMAP)

Gastric Cancer | Esophageal Cancer

Australia
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Breast Cancer

United States, Canada, Spain, Belgium, China, Italy, Korea, Republic of, Taiwan, Australia, Japan, Brazil, France, Germany, United Kingdom, Hong Kong
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer (BALI-1)

Breast Neoplasm

Spain, United Kingdom, Germany, Australia, Austria, Belgium, Israel, New Zealand, Portugal, Italy, Ireland
Hoffmann-La Roche
Genentech, Inc.; Breast International Group

Active, not recruiting

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Breast Cancer

United States, Belgium, Canada, Australia, Austria, Bulgaria, China, Croatia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Panama, Slovenia, Spain, Taiwan, United Kingdom, Colombia, Czechia, El Salvador and more
Lawson Health Research Institute

Completed

PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy (PROPS)

Prostate Cancer

United Kingdom, Australia, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer

Breast Cancer

United States, Canada, Australia, Ireland
The University of New South Wales
National Health and Medical Research Council, Australia; Novo Nordisk A/S; Sydney...

Completed

Rosiglitazone and Insulin in T1DM Adolescents

Type 1 Diabetes | Puberty: >Tanner 2 Breast Development or Testis >4ml

Australia
Carina Biotech Limited

Recruiting

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

Australia
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic

Canada, Germany, United States, Israel, Puerto Rico, Taiwan, Korea, Republic of, Australia, Chile, China, France, Norway, Czechia, Finland, Hong Kong, Netherlands, Poland, Spain, Sweden, Turkey, Denmark, Hungary, Italy, United Kingdom, ... and more
Puma Biotechnology, Inc.

Completed

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET)

Breast Cancer

United States, Spain, Korea, Republic of, China, United Kingdom, Canada, France, Australia, Denmark, Switzerland, Japan, Malaysia, Italy, Singapore, Taiwan, Belgium, Croatia, Czechia, Romania, Germany, Bahamas, Brazil, Bulgaria, Colombia and more
University of Rostock
German Breast Group; German Cancer Aid

Active, not recruiting

Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery (INSEMA)

Breast Cancer

Austria, Germany
British Columbia Cancer Agency
Sanofi; Ozmosis Research Inc.

Unknown

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-Resistant Prostatic Cancer

Canada, Australia
Stemline Therapeutics, Inc.

Active, not recruiting

Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD)

Breast Cancer

United States, Spain, Israel, Italy, Korea, Republic of, Australia, United Kingdom, Hungary, France, Portugal, Belgium, Ireland, Argentina, Austria, Canada, Denmark, Greece
Medical University of Graz

Recruiting

PROM Project Urology

Urologic Diseases | Surgery | Urologic Cancer

Austria
Exelixis

Recruiting

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Cervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid Tumors

United States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Urothelial Carcinoma | Differentiated Thyroid Cancer | Gastroesophageal... and other conditions

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Pfizer
Medivation, Inc.

Completed

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Australia, United States, Spain, France, Korea, Republic of, Germany, Austria, United Kingdom, Belgium, Hungary, Italy, Brazil, Netherlands, Poland
ETOP IBCSG Partners Foundation
NSABP Foundation Inc

Completed

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer (CALOR)

Breast Cancer

Spain, United States, Australia, Belgium, Switzerland, Canada, Peru, Netherlands, Hungary, South Africa
Sanofi

Terminated

To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent

Breast Neoplasms

Poland, Austria
Novartis Pharmaceuticals

Active, not recruiting

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (AMALEE)

Breast Cancer

United States, South Africa, Austria, Hungary, Germany, Czechia, France, Russian Federation, Thailand, Belgium, Bulgaria, Lithuania, Jordan, Sweden, Finland, Peru, Colombia, Portugal, Canada, Brazil, India, Argentina, Costa Rica
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients (PLATO)

Prostate Cancer

United States, Australia, Spain, United Kingdom, Denmark, Belgium, Slovakia, Finland, Italy, France, Sweden
Queen Mary University of London
Cancer Research UK

Completed

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ (IBIS-II DCIS)

Breast Cancer

France, Switzerland, Ireland, United Kingdom, Italy, Australia, Austria, Belgium, Chile, Germany, Hungary, Malta, Sweden, Turkey
Spago Nanomedical AB

Recruiting

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer (Tumorad)

Solid Tumor | Metastatic Cancer | Refractory Cancer | Locally Advanced Solid Tumor | Unresectable Solid Tumor | Recurrent Solid Tumor

Australia
AstraZeneca

Completed

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

Breast Cancer | Metastasis

United States, Australia, Brazil, France, Italy, Mexico, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Poland, Japan, Argentina, Austria, Canada, Hungary, Israel, Netherlands, New Zealand, Portugal, Taiwan, Germany, Finlan... and more
Hoffmann-La Roche

Terminated

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER)

Breast Cancer

Italy, United States, Korea, Republic of, Canada, Czechia, Spain, Australia, Bulgaria, China, Finland, France, Greece, Poland, Portugal, Taiwan, Thailand, Turkey, Colombia, Bosnia and Herzegovina, Mexico, Peru, Romania, Russian Federation and more
Eli Lilly and Company
NSABP Foundation Inc

Active, not recruiting

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

Breast Cancer

United States, Spain, China, Germany, Canada, Taiwan, United Kingdom, Singapore, Italy, Australia, Japan, Hungary, Russian Federation, India, Belgium, New Zealand, Austria, Saudi Arabia, France, Czechia, Korea, Republic of, Finland, Argentin... and more
Novartis Pharmaceuticals

Completed

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1)

Breast Cancer

China, United States, France, Italy, United Kingdom, Taiwan, Turkey, Egypt, Germany, Hong Kong, Belgium, Canada, Russian Federation, Lebanon, Japan, Australia, Greece, Korea, Republic of, Ireland, Peru, Argentina, Brazil, Colombia, South... and more
Trans Tasman Radiation Oncology Group
Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Urological...

Active, not recruiting

Radiotherapy - Adjuvant Versus Early Salvage (RAVES)

Prostate Cancer

Australia, New Zealand
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)

Breast Cancer

United States, Korea, Republic of, United Kingdom, Australia, Belgium, China, Denmark, France, Hungary, Portugal, Spain, Taiwan, Thailand, Canada, Italy, Argentina, Brazil, Poland, Singapore, Germany, Greece, Hong Kong, Ukraine, Russian... and more
AstraZeneca

Recruiting

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5

Canada, Spain, China, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Neoplasms

United States, Australia
BeiGene

Terminated

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)

United States, Australia, Puerto Rico, Spain
Janssen-Cilag Ltd.

Recruiting

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide (ArtemisPRO)

Metastatic Hormone-sensitive Prostate Cancer

France, Germany, Spain, Greece, Austria, United Kingdom
Bayer

Recruiting

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Biochemically Recurrent Prostate Cancer

Austria, Spain, United States, Australia, Brazil, France, Germany, Taiwan, Denmark, China, Netherlands, Portugal, Japan, Canada, Finland, Italy, Hungary, United Kingdom, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

Spain, China, United States, Italy, United Kingdom, Korea, Republic of, Belgium, France, Germany, Poland, Japan, Vietnam, Canada, Brazil, India, Malaysia, Taiwan, Thailand, Australia, Austria, Turkey, Hong Kong, Bulgaria, Switzerland, H... and more
Eli Lilly and Company

Completed

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (neoMONARCH)

Breast Cancer | Early-Stage Breast Carcinoma | Hormone Receptor Positive Tumor

United States, Canada, Korea, Republic of, Italy, Austria, Belgium, Germany, Netherlands, Spain, Taiwan
Bristol-Myers Squibb
Astellas Pharma Inc; Clovis Oncology, Inc.

Active, not recruiting

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)

Prostate Cancer

United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Mexico, Spain
Hoffmann-La Roche

Completed

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

Breast Cancer

Israel, Italy, Poland, Spain, China, Hong Kong, Australia, Canada, Sweden, Switzerland, United States, South Africa, United Kingdom, Germany, Portugal, Taiwan, Japan, Russian Federation, Singapore, France, Netherlands, Belgium, Austria and more

Clinical Trials on Male Breast Cancer in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations